News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.
FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease
The FDA granted 510(k) clearance to Fujirebio's Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio test, the first blood test cleared to help diagnose Alzheimer's in adults 55 and older with signs of cognitive decline. In FDA's review, positive results correctly identified amyloid plaques 91.7% of the time and negative results correctly ruled them out 97.3% of the time.
Why it matters: A simple blood draw can now help identify amyloid plaques without a spinal tap or PET scan, potentially speeding diagnosis and lowering costs, though FDA stressed it isn't a stand-alone diagnostic test.
Read at FDA → Archived copy (10 Oct 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.